These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 20175227)
1. [3H]4-(dimethylamino)-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl) butyl)benzamide: a selective radioligand for dopamine D(3) receptors. II. Quantitative analysis of dopamine D(3) and D(2) receptor density ratio in the caudate-putamen. Xu J; Hassanzadeh B; Chu W; Tu Z; Jones LA; Luedtke RR; Perlmutter JS; Mintun MA; Mach RH Synapse; 2010 Jun; 64(6):449-59. PubMed ID: 20175227 [TBL] [Abstract][Full Text] [Related]
2. [(3)H]4-(Dimethylamino)-N-[4-(4-(2-methoxyphenyl)piperazin- 1-yl)butyl]benzamide, a selective radioligand for dopamine D(3) receptors. I. In vitro characterization. Xu J; Chu W; Tu Z; Jones LA; Luedtke RR; Perlmutter JS; Mintun MA; Mach RH Synapse; 2009 Sep; 63(9):717-28. PubMed ID: 19425052 [TBL] [Abstract][Full Text] [Related]
3. Pharmacology of [3H]R(+)-7-OH-DPAT binding in the rat caudate-putamen. Hillefors M; von Euler G Neurochem Int; 2001 Jan; 38(1):31-42. PubMed ID: 10913686 [TBL] [Abstract][Full Text] [Related]
4. (-)S amisulpride binds with high affinity to cloned dopamine D(3) and D(2) receptors. Castelli MP; Mocci I; Sanna AM; Gessa GL; Pani L Eur J Pharmacol; 2001 Dec; 432(2-3):143-7. PubMed ID: 11740949 [TBL] [Abstract][Full Text] [Related]
5. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Narendran R; Slifstein M; Guillin O; Hwang Y; Hwang DR; Scher E; Reeder S; Rabiner E; Laruelle M Synapse; 2006 Dec; 60(7):485-95. PubMed ID: 16952157 [TBL] [Abstract][Full Text] [Related]
6. The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ antagonist [³H]raclopride and the novel CB₁ inverse agonist [¹²⁵I]SD7015. Farkas S; Nagy K; Jia Z; Harkany T; Palkovits M; Donohou SR; Pike VW; Halldin C; Máthé D; Csiba L; Gulyás B Brain Res Bull; 2012 Apr; 87(6):504-10. PubMed ID: 22421165 [TBL] [Abstract][Full Text] [Related]
7. II. Localization and characterization of dopamine D4 binding sites in rat and human brain by use of the novel, D4 receptor-selective ligand [3H]NGD 94-1. Primus RJ; Thurkauf A; Xu J; Yevich E; McInerney S; Shaw K; Tallman JF; Gallagher DW J Pharmacol Exp Ther; 1997 Aug; 282(2):1020-7. PubMed ID: 9262371 [TBL] [Abstract][Full Text] [Related]
8. Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment. Tarazi FI; Florijn WJ; Creese I Neuroscience; 1997 Jun; 78(4):985-96. PubMed ID: 9174067 [TBL] [Abstract][Full Text] [Related]
9. Characterization of (125)I-IABN, a novel azabicyclononane benzamide selective for D2-like dopamine receptors. Luedtke RR; Freeman RA; Boundy VA; Martin MW; Huang Y; Mach RH Synapse; 2000 Dec; 38(4):438-49. PubMed ID: 11044891 [TBL] [Abstract][Full Text] [Related]
10. Autoradiographic mapping of dopamine-D2/D3 receptor stimulated [35S]GTPgammaS binding in the human brain. Sóvágó J; Makkai B; Gulyás B; Hall H Eur J Neurosci; 2005 Jul; 22(1):65-71. PubMed ID: 16029196 [TBL] [Abstract][Full Text] [Related]
11. Characterization of [(3) H]LS-3-134, a novel arylamide phenylpiperazine D3 dopamine receptor selective radioligand. Rangel-Barajas C; Malik M; Taylor M; Neve KA; Mach RH; Luedtke RR J Neurochem; 2014 Nov; 131(4):418-31. PubMed ID: 25041389 [TBL] [Abstract][Full Text] [Related]
12. Persistent, specific and dose-dependent effects of toluene exposure on dopamine D2 agonist binding in the rat caudate-putamen. Hillefors-Berglund M; Liu Y; von Euler G Toxicology; 1995 Jun; 100(1-3):185-94. PubMed ID: 7624876 [TBL] [Abstract][Full Text] [Related]
13. [3H]raclopride binding to brain tissue from subjects with schizophrenia: methodological aspects. Dean B; Pavey G; Opeskin K Neuropharmacology; 1997 Jun; 36(6):779-86. PubMed ID: 9225305 [TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo comparison of [³H](+)-PHNO and [³H]raclopride binding to rat striatum and lobes 9 and 10 of the cerebellum: a method to distinguish dopamine D₃ from D₂ receptor sites. Kiss B; Horti F; Bobok A Synapse; 2011 Jun; 65(6):467-78. PubMed ID: 20936685 [TBL] [Abstract][Full Text] [Related]
15. Autoradiographic visualization of dopamine D-2 receptors in the monkey brain using the selective benzamide drug [3H]raclopride. Köhler C; Radesäter AC Neurosci Lett; 1986 May; 66(1):85-90. PubMed ID: 2940480 [TBL] [Abstract][Full Text] [Related]
16. [3H]-quinelorane binds to D2 and D3 dopamine receptors in the rat brain. Gackenheimer SL; Schaus JM; Gehlert DR J Pharmacol Exp Ther; 1995 Sep; 274(3):1558-65. PubMed ID: 7562534 [TBL] [Abstract][Full Text] [Related]
17. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168 [TBL] [Abstract][Full Text] [Related]
18. Concentration of receptor and ligand revisited in a modified receptor binding protocol for high-affinity radioligands: [3H]Spiperone binding to D2 and D3 dopamine receptors. Zhen J; Antonio T; Dutta AK; Reith ME J Neurosci Methods; 2010 Apr; 188(1):32-8. PubMed ID: 20122961 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the in vitro receptor binding properties of N-[3H]methylspiperone and [3H]raclopride to rat and human brain membranes. Hall H; Wedel I; Halldin C; Kopp J; Farde L J Neurochem; 1990 Dec; 55(6):2048-57. PubMed ID: 1977888 [TBL] [Abstract][Full Text] [Related]